S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Central Maine Power, EDP Renewables and Emera Maine Advance Northern Maine Wind (2015/1/7)|
|NephroGenex Announces that the European Medicines Agency Supports the Company’s Study Design for Ongoing Trial in Diabetic Nephropathy (2015/1/7)|
|AVEO Receives Confirmation of Eligibility for Submission of a Tivozanib Marketing Authorization Application to the European Medicines Agency (2015/1/8)|
|The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV™ (oritavancin) and RAPLIXA™ (sealant powder) (2015/1/23)|
|Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma (2015/1/27)|
|ARIAD Announces Commercialization Agreement for Iclusig in Seven Central and Eastern European Countries (2014/12/30)|
|Ligand Partner GlaxoSmithKline Announces EU Regulatory Submission Seeking Additional Indication for Revolade® (2015/2/6)|
|Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA (2014/12/23)|
|Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and Ovarian Cancers (2014/12/22)|
|Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA (2015/1/12)|
Click above to view more mutual fund data and stats for ema - Emera Inc.